Condition: Nasopharyngeal Cancinoma (NPC) · Sponsor: Fudan University
This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
This description comes directly from the study's public registry record.
Hongmei Ying · +8602164175590-86703 · yinghongmei2013@163.com
Fangfang Kong · +8613817283123 · ago123.com@163.com
Always discuss trial participation with your own doctor first.
| Fudan Universtiy Shanghai Cancer Centre | Shanghai, China, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07067268